BioLight Life Sciences Ltd. (IL:BOLT)
TASE:BOLT
Want to see IL:BOLT full AI Analyst Report?
BOLT Stock Chart & Stats
371.40
-0.16(-2.50%)
At close: 4:00 PM EST
371.40
-0.16(-2.50%)
Day’s Range― - ―
52-Week Range209.20 - 661.90
Previous CloseN/A
Volume1.67K
Average Volume (3M)11.86K
Market Cap
₪22.41M
Enterprise Value8.08M
Total Cash (Recent Filing)₪23.65M
Total Debt (Recent Filing)₪772.00K
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-67.20
Shares Outstanding9,079,270
10 Day Avg. Volume7,448
30 Day Avg. Volume11,863
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageConsistently minimal debt materially reduces refinancing and solvency risk over the medium term. A low-leverage capital structure gives management flexibility to fund R&D or secure bridge financing without heavy interest burdens, improving survival odds during extended product development cycles.
Positive Equity CushionDespite erosion, a multi‑million equity base still exists, providing a tangible capital buffer to absorb losses and support financing discussions. That residual equity makes it easier to negotiate debt or equity raises versus a balance sheet already insolvent, sustaining operations while R&D progresses.
Lean Operating BaseA very small headcount implies a low fixed payroll and likely outsourced R&D model, enabling capital efficiency. Structurally, lean staffing reduces ongoing cash burn pressures and allows management to reallocate limited resources or extend runway via contract research and partnerships.
Bears Say
Revenue CollapseDropping to zero revenue signals a pre‑commercial or disrupted business model with no internal cash generation. Over the medium term this prevents self‑funding of operations, increases dependency on external capital, and heightens execution risk tied to successful commercialization or milestone events.
Persistent Cash BurnSustained negative operating and free cash flow indicate the company is consuming cash rather than generating it. This structural cash burn forces repeated financing, elevates dilution and refinancing risk, and makes long‑term planning contingent on successful capital raises or cost reductions.
Eroding Returns / CapitalMaterial negative ROE and falling equity reflect that invested capital is not producing returns and is being depleted. Over months this weakens the balance sheet cushion, raises cost of capital, and constrains strategic options like partnerships or acquisitions that require a stronger financial profile.
BOLT FAQ
What was BioLight Life Sciences Ltd.’s price range in the past 12 months?
BioLight Life Sciences Ltd. lowest stock price was 209.20 and its highest was 661.90 in the past 12 months.
What is BioLight Life Sciences Ltd.’s market cap?
BioLight Life Sciences Ltd.’s market cap is ₪22.41M.
When is BioLight Life Sciences Ltd.’s upcoming earnings report date?
BioLight Life Sciences Ltd.’s upcoming earnings report date is Aug 24, 2026 which is in 125 days.
How were BioLight Life Sciences Ltd.’s earnings last quarter?
BioLight Life Sciences Ltd. released its earnings results on Apr 01, 2026. The company reported -67.2 earnings per share for the quarter, missing the consensus estimate of N/A by -67.2.
Is BioLight Life Sciences Ltd. overvalued?
According to Wall Street analysts BioLight Life Sciences Ltd.’s price is currently Overvalued.
Does BioLight Life Sciences Ltd. pay dividends?
BioLight Life Sciences Ltd. does not currently pay dividends.
What is BioLight Life Sciences Ltd.’s EPS estimate?
BioLight Life Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioLight Life Sciences Ltd. have?
BioLight Life Sciences Ltd. has 9,079,270 shares outstanding.
What happened to BioLight Life Sciences Ltd.’s price movement after its last earnings report?
BioLight Life Sciences Ltd. reported an EPS of -67.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioLight Life Sciences Ltd.?
Currently, no hedge funds are holding shares in IL:BOLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLight Life Sciences Ltd.
BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival implant; OphRx that develops drugs for treating eye diseases; and Peripherex, which develops solutions for at-home and in-office diagnosis and monitoring of peripheral vision impairment used by eye care and other providers to diagnose and monitor glaucoma and other diseases. Its pipeline also include AEYE that develops artificial intelligence solutions for a variety of retinal diseases; Tarsier, which develops TRS 01 based on its technological platform for the treatment of Uveitis in patients suffering from high IPO; Belkin Vision that develops clinic fast and automatic laser device to enable glaucoma patients to receive short & effective treatments as treatment to lower IOP; and Sanoculis, which develops an innovative surgical procedure for the treatment of the Glaucoma. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was incorporated in 2005 and is based in Tel Aviv, Israel.